Intercept Pharmaceuticals (NASDAQ:ICPT) will announce its Q4 2017 earnings results before the market opens on Wednesday, February 21st. Analysts expect the company to announce earnings of ($3.39) per share for the quarter.
Shares of Intercept Pharmaceuticals (NASDAQ ICPT) opened at $53.41 on Wednesday. Intercept Pharmaceuticals has a twelve month low of $51.05 and a twelve month high of $135.59. The company has a market capitalization of $1,340.00, a P/E ratio of -3.61 and a beta of -2.13. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15.
Several analysts recently commented on ICPT shares. Wedbush reiterated a “buy” rating and issued a $253.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, January 5th. Deutsche Bank started coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They issued a “buy” rating and a $106.00 target price on the stock. Goldman Sachs Group cut Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a report on Wednesday, November 1st. Five investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $132.90.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.